STRONG-HF study results demonstrate clear benefits for acute heart failure patients

STRONG-HF study primary outcomes showed significant reduction of all cause death or acute heart failure readmissions, at day 180, when the study strategy was implementedRapid, simultaneous up-titration of therapies, and close follow-up, led to increased patient quality of life.The RocheElecsys® NT-proBNP biomarker is an integral part of the treatment strategy, comprising rapid up-titration and close follow up after an acute heart failure admissionBasel, 9 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced publication of the Safety, Tolerability and Efficacy of Rapid Optimization of Heart Failure (STRONG-HF) study in patients hospitalised for acute heart failure. The study, which includes utilisation of the Roche Elecsys NT-proBNP biomarker, was terminated early for superior efficacy in the active arm of the study versus the usual standard of care, as it was considered unethical to continue with usual care.Implementing thestudy ’s strategy in routine clinical practice, has the opportunity to significantly reduce all cause deaths or heart failure readmissions and increase quality of life for more heart failure patients, evaluated after six months, compared to current patient management practices. The results have been sha red at the American Heart Association (AHA) Late-Breaking Scientific Session and published simultaneously in the Lancet.1" We are very excited about the positive outcome of this Investigator Initiated Study, which Roche supported, as it has ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news